Subgroup analysis of tumor DNA results showed that the median survival of patients with NRAS G12/G13 mutations was shorter than that of patients without NRAS G12/G13 mutations (9.6 months vs. 59 months, P=0.0201) (Figure 2C). Here, NRAS is linked to neoplasm.